IF 1.9 4区医学

Biomarkers Pub Date : 2025-10-01 DOI: 10.1080/1354750X.2025.2556170

Soumya Patil, Raushan Kumar Chaudhary, Prakash Patil, Praveenkumar Shetty, Vijith Vittal Shetty, Krishna Sharan, Uday Venkat Mateti

{"title":"Unveiling the oncogenic role and prognostic value of ACTL6A in cancer: a systematic review and meta-analysis.","authors":"Soumya Patil, Raushan Kumar Chaudhary, Prakash Patil, Praveenkumar Shetty, Vijith Vittal Shetty, Krishna Sharan, Uday Venkat Mateti","doi":"10.1080/1354750X.2025.2556170","DOIUrl":"10.1080/1354750X.2025.2556170","url":null,"abstract":"Background: Actin-like protein 6 A (ACTL6A), a subunit of SWItch/sucrose non-fermentable (SWI/SNF) complex has emerged as a key player in cancer progression. Despite growing evidence of its oncogenic potential, a comprehensive evaluation of its role in tumourigenesis and clinical outcomes remains warranted. This systematic review and meta-analysis aim to elucidate the role of ACTL6A in cancer pathophysiology and its prognostic significance.Methods: A systematic search in PubMed, Scopus and Web of Science was conducted from inception to 31 December 2024, using the keywords 'ACTL6A' and 'Cancer'. Studies investigating ACTL6A's role in cancer and those reporting hazard ratios (HRs) for ACTL6A expression in human samples were considered for systematic review and meta-analysis, respectively.Results: A total of 39 studies were included in systematic review which collectively reported the role of ACTL6A in tumuorigenesis, invasion and metastasis via HIPPO-YAP, PI3K/AKT, NOTCH and Wnt/β-catenin pathways. Six studies (n = 863) qualified for meta-analysis, revealing that ACTL6A overexpression was significantly associated with poor overall survival (OS) (p = 0.001), larger tumour size (p < 0.01) and higher tumour grade (p = 0.002).Conclusion: ACTL6A is a critical oncogenic driver which promotes cancer progression and poor clinical outcomes. ACTL6A may serve as a promising prognostic marker, paving the way for targeted therapeutic strategies in oncology.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-13"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of the serum creatinine to total bilirubin ratio in psoriasis patients treated with biological agents: Significant reduction following IL-17 inhibitor therapy. 生物制剂治疗银屑病患者血清肌酐与总胆红素比值的评价：IL-17抑制剂治疗后显著降低。

IF 1.9 4区医学

Biomarkers Pub Date : 2025-09-30 DOI: 10.1080/1354750X.2025.2568858

Funda Tamer, Yusuf Can Edek, Emre Guven, Esra Adisen

{"title":"Evaluation of the serum creatinine to total bilirubin ratio in psoriasis patients treated with biological agents: Significant reduction following IL-17 inhibitor therapy.","authors":"Funda Tamer, Yusuf Can Edek, Emre Guven, Esra Adisen","doi":"10.1080/1354750X.2025.2568858","DOIUrl":"https://doi.org/10.1080/1354750X.2025.2568858","url":null,"abstract":"Introduction: High serum creatinine to total bilirubin ratio has been associated with an increased risk of developing hypertension. We evaluated the effect of biological agents on serum creatinine to total bilirubin ratio in patients with psoriasis.Methods: Serum creatinine and total bilirubin levels of patients were reviewed between June 2018 and October 2023.Results: This study included 302 patients, 143 (47.4%) females and 159 (52.6%) males with a mean age of 49.46 ± 13.82 years. The creatinine to total bilirubin ratio was higher in males than in females (p = 0.028), and in patients with comorbidities compared to those without (p = 0.031). Six months after biological agent treatment, serum total bilirubin levels increased (p = 0.010), while the creatinine to total bilirubin ratio significantly decreased (p = 0.038) in all patients. Serum creatinine to total bilirubin ratio decreased (p = 0.031) in patients who received IL-17 inhibitors after 6 months. Among them, patients treated with ixekizumab showed a statistically significantly decrease in creatinine to total bilirubin ratio (p = 0.015).Conclusion: The decrease in creatinine to total bilirubin ratio after 6 months of treatment was statistically significant only in patients treated with IL-17 inhibitors, particularly ixekizumab. Therefore, we suggest that IL-17 inhibitors may have a protective role against hypertension in patients with psoriasis.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-13"},"PeriodicalIF":1.9,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Circulating miR-27a as a Non-Invasive Diagnostic Biomarker to Differentiate Malignant from Benign Breast Lesions: A Preliminary Study. 循环miR-27a作为区分乳腺良恶性病变的非侵入性诊断生物标志物：一项初步研究

IF 1.9 4区医学

Biomarkers Pub Date : 2025-09-29 DOI: 10.1080/1354750X.2025.2568870

Maryam Jamal, Shivani Jaswal, Jasbinder Kaur, Vishal Sharma, Usha Dalal, Ravinder Kaur, Uma Handa, Manpreet Kaur

{"title":"Circulating miR-27a as a Non-Invasive Diagnostic Biomarker to Differentiate Malignant from Benign Breast Lesions: A Preliminary Study.","authors":"Maryam Jamal, Shivani Jaswal, Jasbinder Kaur, Vishal Sharma, Usha Dalal, Ravinder Kaur, Uma Handa, Manpreet Kaur","doi":"10.1080/1354750X.2025.2568870","DOIUrl":"https://doi.org/10.1080/1354750X.2025.2568870","url":null,"abstract":"BackgroundBreast cancer is the most commonly diagnosed cancer among women worldwide, with no single biomarker yet validated for reliable early diagnosis. miRNAs have emerged as potential circulating biomarkers for several diseases. miR-27a has shown a multifaceted role in the pathogenesis of breast cancer and may be explored for its diagnostic potential. Similarly, soluble HER-2/neu can be assessed for its potential in detecting the presence of tissue HER-2 receptors in breast cancer.MethodsNinety-four patients with breast lumps (BIRADS III or above) were enrolled. Diagnosis and grading were confirmed by biopsy. Serum miRNA was extracted, and miR-27a expression was measured via RT-PCR using RNU6 as a control. sHER-2 levels were assessed using ELISA. Statistical analyses included chi-square, Mann-Whitney U, Kruskal-Wallis, and ROC curve analysis.ResultsmiR-27a expression was significantly higher in breast cancer patients than in those with benign tumors (p < 0.0001), correlating with tumor size, grade, lymph node involvement, and metastasis (p < 0.05). ROC analysis revealed a cut-off >10.31 (AUC 0.971, sensitivity 93.0%, specificity 89.2%). sHER-2 levels were significantly elevated in tissue HER-2 positive breast cancer cases (p < 0.0001).ConclusionmiR27a shows strong potential to be used as a biomarker for breast cancer diagnosis and prognosis. sHER-2 effectively differentiated between the HER-2 status of breast cancer. Larger studies with follow-up are needed for clinical validation.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-20"},"PeriodicalIF":1.9,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oxidative DNA damage may promote the development of endometriosis by activating telomerase and extending telomere length: a meta-analysis. 氧化性DNA损伤可能通过激活端粒酶和延长端粒长度来促进子宫内膜异位症的发展：一项荟萃分析。

IF 1.9 4区医学

Biomarkers Pub Date : 2025-09-16 DOI: 10.1080/1354750X.2025.2557452

Huanli He, Xiaohui Yang, Kai Wang, Qingjian Ye

{"title":"Oxidative DNA damage may promote the development of endometriosis by activating telomerase and extending telomere length: a meta-analysis.","authors":"Huanli He, Xiaohui Yang, Kai Wang, Qingjian Ye","doi":"10.1080/1354750X.2025.2557452","DOIUrl":"10.1080/1354750X.2025.2557452","url":null,"abstract":"Objective: To investigate the associations between oxidative DNA damage biomarkers (levels of 8-hydroxy-2'-deoxyguanosine [8-OHdG], telomere length [TL], human telomerase reverse transcriptase [hTERT], telomerase activity [TA] and polymorphisms of human 8-oxoguanine glycosylase 1 [hOGG1] or X-ray repair cross-complementing group 4 [XRCC4]) and endometriosis (EMT) by a meta-analysis.Methods: Five databases were searched until August 2024. Stata version 15.0 was used to estimate pooled odds ratio (OR) or standardized mean difference (SMD) with 95% confidence intervals (CIs).Results: Forty-two studies were included. Overall meta-analysis revealed significantly elevated 8-OHdG (SMD = 1.84; 95%CI = 1.29-2.39), TA (SMD = 3.03; 95%CI = 2.07-4.00) and hTERT (SMD = 2.55; 95%CI = 1.55-3.55) in EMT women compared to controls. Women carrying GG genotype (vs. GC+CC: OR = 1.34; 95%CI = 1.00-1.78) of hOGG1 rs1052133, TT genotype (vs. TG+GG: OR = 2.67; 95%CI = 1.63-4.38) and T allele (vs. G: OR = 3.49; 95%CI = 2.27-5.35) of XRCC4 rs6869366 had a higher risk of developing EMT. Subgroup and trim-and-fill analyses indicated longer TL was a risk factor for EMT.Conclusions: 8-OHdG, TA, hTERT, TL, rs1052133 and rs6869366 represent potential prediction biomarkers and treatment targets for EMT.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-15"},"PeriodicalIF":1.9,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Placenta specific 1: a novel marker for detection of metastasis in mouse model of breast cancer. 胎盘特异性1：检测乳腺癌小鼠模型转移的新标志物。

IF 1.9 4区医学

Biomarkers Pub Date : 2025-09-10 DOI: 10.1080/1354750X.2025.2556166

Sadegh Safaei, Masoumeh Dehghan Manshadi, Hannaneh Golshahi, Farideh Hashemi, Farhang Sasani, Zahra Madjd, Roya Ghods

{"title":"Placenta specific 1: a novel marker for detection of metastasis in mouse model of breast cancer.","authors":"Sadegh Safaei, Masoumeh Dehghan Manshadi, Hannaneh Golshahi, Farideh Hashemi, Farhang Sasani, Zahra Madjd, Roya Ghods","doi":"10.1080/1354750X.2025.2556166","DOIUrl":"10.1080/1354750X.2025.2556166","url":null,"abstract":"Background: Placental-specific 1 (Plac1), with no expression in normal tissues, is expressed in different cancers. Therefore, the potential application of Plac1 to detect metastasis was investigated in breast cancer model.Methods: A spontaneous metastasis model was established using 4T1 cells. FDG-PET and histological analysis were used to detect metastasis. Plac1 expression was assessed in a wide range of tumor-bearing and normal mice tissues by RT-qPCR. The sensitivity of Plac1-positive cell detection was examined by 4T1 serial dilution in Plac1-negative cells.Results: Plac1 was not expressed in normal mouse tissues (n = 6), except in the brain (6/6, dCT = -10.85). 4T1 cell line (dCT = 0.65) and 4T1-induced tumor (dCT = -0.29) were positive for Plac1 expression. PET imaging and histopathology analysis demonstrated metastases in the lung, liver, and spleen of tumor-bearing mice. Plac1 expression was confirmed in lung (6/6, dCT = -1.52), liver (6/6, dCT = -2.37), spleen (6/6, dCT = -3.7), kidney (2/6, dCT = -40.00), brain (6/6, dCT = -7.47), and blood (6/6, dCT = -3.35) of tumor-bearing mice. The sensitivity of detecting tumor cells is at least one cell per million cells.Conclusions: Plac1 is a novel marker with high specificity and sensitivity for detecting metastasis in breast cancer. These findings provide a rationale for human studies.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-13"},"PeriodicalIF":1.9,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic role of Naples prognostic score in lung cancer: a meta-analysis. 那不勒斯预后评分在肺癌预后中的作用：一项meta分析。

IF 1.9 4区医学

Biomarkers Pub Date : 2025-09-09 DOI: 10.1080/1354750X.2025.2556171

Junrong Yang, Hui Li, Liangqin Li, Jing Lv

{"title":"Prognostic role of Naples prognostic score in lung cancer: a meta-analysis.","authors":"Junrong Yang, Hui Li, Liangqin Li, Jing Lv","doi":"10.1080/1354750X.2025.2556171","DOIUrl":"10.1080/1354750X.2025.2556171","url":null,"abstract":"Purpose: To clarify the association of pretreatment Naples prognostic score (NPS) with long-term survival among lung cancer patients.Methods: EMBASE, Web of Science, PubMed and CNKI databases were searched up to April 16, 2024. Primary outcomes included the overall survival (OS), progression-free survival (PFS) and cancer-specific survival (CSS). Hazard ratios (HRs) with 95% confidence intervals (CIs) were combined and subgroup analysis stratified by the pathological type and treatment was performed.Results: Twelve studies with 3089 patients were included and most patients were from China. Pooled results demonstrated that elevated NPS was related to poor OS (HR = 2.82, 95% CI: 1.88-4.25, P < 0.001), PFS (HR = 2.75, 95% CI: 1.89-4.01, P < 0.001) and CSS (HR = 3.5, 95% CI: 1.6-7.9, P = 0.002). Besides, subgroup analysis based on the pathological type [non-small cell lung cancer (NSCLC) vs small cell lung cancer (SCLC)] and treatment (surgery vs non-surgery) manifested similar results.Conclusion: Pretreatment NPS is associated with long-term prognosis in lung cancer and patients with elevated NPS are more likely to experience poor survival. However, more studies are needed to verify above findings due to limitations in this meta-analysis.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-8"},"PeriodicalIF":1.9,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combined plasma levels of A-type-natriuretic peptide and adrenomedullin are associated with appropriate anti-arrhythmia therapy in patients with an implantable cardioverter defibrillator but no prior device therapy. a型利钠肽和肾上腺髓质素联合血浆水平与植入心律转复除颤器但未接受器械治疗的患者适当的抗心律失常治疗相关

IF 1.9 4区医学

Biomarkers Pub Date : 2025-09-08 DOI: 10.1080/1354750X.2025.2553630

Farzin Beygui, Vincent Roule, Estelle Gandjbakhch, Pierre Ollitraut, Johanne Silvain, Paul Milliez, Nicolas Vignolles, Michel Zeitouni, Paul Guedeney, Laure Champ-Rigot, Katrien Blanchart, Gilles Montalescot

{"title":"Combined plasma levels of A-type-natriuretic peptide and adrenomedullin are associated with appropriate anti-arrhythmia therapy in patients with an implantable cardioverter defibrillator but no prior device therapy.","authors":"Farzin Beygui, Vincent Roule, Estelle Gandjbakhch, Pierre Ollitraut, Johanne Silvain, Paul Milliez, Nicolas Vignolles, Michel Zeitouni, Paul Guedeney, Laure Champ-Rigot, Katrien Blanchart, Gilles Montalescot","doi":"10.1080/1354750X.2025.2553630","DOIUrl":"10.1080/1354750X.2025.2553630","url":null,"abstract":"Background: Identifying patients benefiting from implantable cardioverter defibrillators (ICD) especially when replacing one that has never served may be challenging.Objectives: We assessed the association between plasma levels of mid-regional-pro-A-type-natriuretic peptide (ANP), Mid-regional-pro-adrenomedullin (ADM) and aldosterone and, appropriate Implantable Cardioverter Defibrillator (ICD)-therapy in patients with an ICD but no prior therapy.Methods: A cohort of 331 consecutive patients with an ICD but no prior ICD-therapy was prospectively included in 2 centers and followed-up for a median of 7.9 years. Plasma aldosterone, ANP and ADM levels were measured at inclusion. The primary outcome was the occurrence of appropriate ICD-therapy.Results: Appropriate ICD-therapy and death occurred in 106(32%) and 114(34%) patients respectively. Rates of ICD generator replacement were 62% regardless of ICD-therapy. The multivariable model showed significant relationships between ANP > median (adjusted HR 1.73[95% CI 1.04-2.86]) and ADM > median (HR 0.53 [95% CI 0.32-0.89]) but not aldosterone, and ICD-therapy. The Fine and Gray analysis accounting mortality as a competing risk showed similar results.Conclusions: The combination of ANP and ADM are independently associated with the risk of ICD-therapy in patients with an ICD that has never served, and may participate in stratifying patients who may benefit most from ICD generator replacement.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-9"},"PeriodicalIF":1.9,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multidimensional metabolic profiling in carbon monoxide poisoning: acid-base disturbances correlate with neurological severity. 一氧化碳中毒的多维代谢谱分析：酸碱紊乱与神经系统严重程度相关。

IF 1.9 4区医学

Biomarkers Pub Date : 2025-09-04 DOI: 10.1080/1354750X.2025.2551303

Weiguang Wang, Huihua Huang, Xianwei Xiong, Changsheng Ye, Jin Huang, Yong Ai Ling

{"title":"Multidimensional metabolic profiling in carbon monoxide poisoning: acid-base disturbances correlate with neurological severity.","authors":"Weiguang Wang, Huihua Huang, Xianwei Xiong, Changsheng Ye, Jin Huang, Yong Ai Ling","doi":"10.1080/1354750X.2025.2551303","DOIUrl":"10.1080/1354750X.2025.2551303","url":null,"abstract":"Background: Acute carbon monoxide poisoning triggers complex metabolic derangements including acidosis and alkalosis, but their correlation with neurological injury severity remains insufficiently characterized clinically.Methods: Consecutive poisoning patients (age ≥14) admitted between January 2019 and February 2025 were classified by neurological impairment severity. Acid-base parameters were analysed using Kruskal-Wallis tests, Spearman's correlation, and principal component analysis with varimax rotation.Results: Among 940 patients (37.2% male), participants were categorized into three groups by neurological impairment severity: Mild (n = 597), moderate (n = 225), and severe (n = 118). Severe cases showed lower pH (7.39 vs. 7.41), reduced PaCO2 (34.5 vs. 38.2 mmHg), greater base excess deficit -3.3 vs. 0.4), and higher lactate (3.7 vs. 1.6 mmol/L) (all p < 0.001). Neurological severity positively correlated with lactate (rho = 0.338) and inversely with base excess (rho = -0.268). Principal component analysis identified two components: Factor Component 1 (FAC1) (metabolic compensation, 47-65% variance) and FAC2 (respiratory regulation, 26-41% variance), with FAC1 inversely correlating with severity (rho = -0.319, p < 0.001).Conclusions: Neurological impairment severity shows dose-dependent correlation with metabolic dysfunction (lactate accumulation, mixed metabolic acidosis-respiratory alkalosis). FAC1 (metabolic compensation) is a strong prognostic biomarker in acute carbon monoxide poisoning.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-8"},"PeriodicalIF":1.9,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A diagnostic algorithm to evaluate elevated C-reactive protein levels in juvenile systemic lupus erythematosus. 评估少年系统性红斑狼疮患者c反应蛋白水平升高的诊断算法。

IF 1.9 4区医学

Biomarkers Pub Date : 2025-09-04 DOI: 10.1080/1354750X.2025.2556159

Ezgi Deniz Batu, Seher Sener, Sila Atamyildiz Ucar, Zeynep Balik, Gulsah Kavrul Kayaalp, Veysel Cam, Emil Aliyev, Yagmur Bayindir, Ozge Basaran, Nuray Aktay Ayaz, Betul Sozeri, Yelda Bilginer, Seza Ozen

{"title":"A diagnostic algorithm to evaluate elevated C-reactive protein levels in juvenile systemic lupus erythematosus.","authors":"Ezgi Deniz Batu, Seher Sener, Sila Atamyildiz Ucar, Zeynep Balik, Gulsah Kavrul Kayaalp, Veysel Cam, Emil Aliyev, Yagmur Bayindir, Ozge Basaran, Nuray Aktay Ayaz, Betul Sozeri, Yelda Bilginer, Seza Ozen","doi":"10.1080/1354750X.2025.2556159","DOIUrl":"10.1080/1354750X.2025.2556159","url":null,"abstract":"Objective: C-reactive protein (CRP) levels are generally not correlated with systemic lupus erythematosus (SLE) disease activity. We aimed to develop an algorithm to evaluate juvenile SLE (JSLE) patients with elevated CRP.Methods: JSLE patients diagnosed at <18 years were included. Each episode of CRP elevation was evaluated separately.Results: Of 190 JSLE patients (F/M:4/1), 88 (46.3%) never had an elevated CRP, while 102 (53.7%) had 174 episodes of CRP elevation. Causes were infection (n = 139), arthritis (n = 15), macrophage activation syndrome (MAS) (n = 9), MAS and infection (n = 3), serositis (n = 6), and vasculitis (n = 2). MAS was more common in the SLE disease activity index (SLEDAI)>4 group, while infections were more frequent in the SLEDAI ≤ 4 group. MAS episodes were more prevalent among patients with CRP >2x the upper limit of normal. We developed an algorithm to prioritize etiology in JSLE patients with elevated CRP. It led to the correct etiology in 164 of 165 episodes (99.4%) in the primary cohort. In an external JSLE cohort including 37 patients with 68 elevated CRP episodes, the algorithm led to the correct etiology in 67 (98.5%).Conclusion: Our algorithm could assist physicians evaluating elevated CRP episodes in JSLE patients. Validation in larger cohorts may improve its performance.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-6"},"PeriodicalIF":1.9,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Involvement of Perk and ATF6 Signal Pathways in Indicating Unfolded Protein Response in Patients with Chronic Lymphocytic Leukaemia. Perk和ATF6信号通路在慢性淋巴细胞白血病患者未折叠蛋白反应中的作用

IF 1.9 4区医学

Biomarkers Pub Date : 2025-08-29 DOI: 10.1080/1354750X.2025.2553628

Nergiz Erkut, Merve Kestane, Selim Demir, Ahmet Mentese, Ozlen Balta, Mehmet Sonmez

{"title":"Involvement of Perk and ATF6 Signal Pathways in Indicating Unfolded Protein Response in Patients with Chronic Lymphocytic Leukaemia.","authors":"Nergiz Erkut, Merve Kestane, Selim Demir, Ahmet Mentese, Ozlen Balta, Mehmet Sonmez","doi":"10.1080/1354750X.2025.2553628","DOIUrl":"https://doi.org/10.1080/1354750X.2025.2553628","url":null,"abstract":"Introduction: PERK, ATF6, and IRE1α signalling pathways are unfolded protein response (UPR) signalling pathways. In this study, we evaluated the effect of PERK and ATF6 signalling pathways, which are UPR signalling pathways, in chronic lymphocytic leukaemia (CLL) patients.Methods: ELISA was performed on peripheral blood plasma samples from CLL patients and the control group for the markers eIF2AK3, GRP78, ATF6, CHOP, HIF-1α and caspase 3.Results: In this study, the levels of eIF2AK3, GRP78, ATF6 and CHOP were higher in the CLL group than in the control group (p = <0.001, p = <0.001, p = <0.001, p = <0.001, respectively). While no difference was observed between the CLL group and the control group in terms of HIF-1α level, caspase 3 level was higher in the CLL group (p = <0.001). There was a positive relationship between the level of HIF-1α and the levels of ATF6 and CHOP (r = 0.648, p = <0.001; r = 0.727, p = <0.001, respectively). Also, a positive correlation was observed between caspase 3 level and ATF6 level (r = 0.301, p = 0.030).Discussion: In this study, markers associated with PERK and ATF6 signalling pathways were higher in CLL patients.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-12"},"PeriodicalIF":1.9,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarkers最新文献